ArticleBJU international2026
Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Not always a perfect match: discrepancies between PSMA PET/CT and MRI in prostate cancer diagnosis and staging.Abdominal radiology (New York) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic performance of different staging modalities and oncological outcomes in patients with intermediate-risk (IR) prostate cancer (PCa) undergoing radical prostatectomy (RP) with pelvic lymph node dissection (PLND). PATIENTS AND
methodsPatients with IR PCa who underwent RP and PLND between 2015 and 2021 were retrospectively analysed. Patients who had received neoadjuvant hormone therapy were excluded. The effectiveness of computed tomography (CT), magnetic resonance imaging (MRI), and prostate-specific membrane antigen-positron emission tomography (PSMA-PET) in detecting lymph node invasion (LNI) was assessed. Kaplan-Meier analysis was used to evaluate biochemical recurrence-free and metastasis-free survival.
resultsAmong 8043 patients with IR PCa undergoing RP with PLND, 624 (7.8%) had LNI. PSMA-PET was performed in 400 patients: six true positives, 40 false negatives, 14 false positives, and 340 true negatives. CT was used in 2079 patients: two true positives, 228 false negatives, seven false positives, and 1842 true negatives. MRI was performed in 148 patients: one true positive, 11 false negatives, and 136 true negatives, with no false positives. Sensitivity was highest for PSMA-PET (13%), followed by MRI (8.3%) and CT (0.9%). Negative predictive values were 92.5% for MRI, 89.5% for PSMA-PET, and 89% for CT. Patients with negative PSMA-PET findings had significantly better biochemical recurrence-free and metastasis-free survival than those with suspicious findings on PSMA-PET.
conclusionsAll evaluated staging modalities demonstrated limited sensitivity in detecting LNI in patients with IR PCa, including PSMA-PET. Given the poor diagnostic performance of conventional imaging, such methods may be omitted in this setting. PSMA-PET may still be considered selectively, as it provides modest sensitivity and prognostic value, although its role remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.